0000899243-22-028246.txt : 20220810
0000899243-22-028246.hdr.sgml : 20220810
20220810160606
ACCESSION NUMBER: 0000899243-22-028246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220808
FILED AS OF DATE: 20220810
DATE AS OF CHANGE: 20220810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALTSHULER DAVID
CENTRAL INDEX KEY: 0001550395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 221151814
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-08
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001550395
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Global Research and CSO
Common Stock
2022-08-08
4
M
0
1304
187.53
A
37381
D
Common Stock
2022-08-08
4
S
0
222
290.32
D
37159
D
Common Stock
2022-08-08
4
S
0
424
291.53
D
36735
D
Common Stock
2022-08-08
4
S
0
210
293.02
D
36525
D
Common Stock
2022-08-08
4
S
0
302
293.99
D
36223
D
Common Stock
2022-08-08
4
S
0
146
295.14
D
36077
D
Stock Option (Right to Buy)
187.53
2022-08-08
4
M
0
1304
0.00
D
2029-02-05
Common Stock
1304
2607
D
Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $290.32 (range $290.05 to $290.64).
Open market sales reported on this line occurred at a weighted average price of $291.53 (range $291.06 to $291.91).
Open market sales reported on this line occurred at a weighted average price of $293.02 (range $292.41 to $293.36).
Open market sales reported on this line occurred at a weighted average price of $293.99 (range $293.58 to $294.26).
Open market sales reported on this line occurred at a weighted average price of $295.14 (range $294.74 to $295.53).
The option vests in 16 quarterly installments from 2/6/2019.
/s/ Joy Liu, Attorney-in-Fact
2022-08-10